- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05153694
Infectious Complications After Cystectomy: A Prospective Observational Study
November 29, 2021 updated by: Benedikt Ebner, Ludwig-Maximilians - University of Munich
In this study, we evaluate peri- and postoperative parameters of patients undergoing a cystectomy and try to find risk factors for infectious complications.
In detail, we analyze their medical history, demographic data, lab values, microbiological tests as well as histological and radiological findings.
Furthermore, after discharging our patients, we send them several follow-up questionnaires at regular intervals and offer them free follow-up examinations.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Benedikt Ebner, Dr.
- Phone Number: 004917655197898
- Email: Benedikt.Ebner@med.uni-muenchen.de
Study Locations
-
-
Outside U.S./Canada
-
Munich, Outside U.S./Canada, Germany, 81377
- Recruiting
- Urology Department - LMU Klinikum
-
Contact:
- Benedikt Ebner
- Phone Number: 017655197898
- Email: Benedikt.Ebner@gmx.at
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients who undergo cystectomy
Description
Inclusion Criteria:
- Disease which requires removal of the urinary bladder
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Infectious Complications
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Gerald Schulz, PD Dr., Ludwig-Maximilians - University of Munich
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
December 1, 2021
Primary Completion (Anticipated)
November 30, 2023
Study Completion (Anticipated)
November 30, 2024
Study Registration Dates
First Submitted
November 29, 2021
First Submitted That Met QC Criteria
November 29, 2021
First Posted (Actual)
December 10, 2021
Study Record Updates
Last Update Posted (Actual)
December 10, 2021
Last Update Submitted That Met QC Criteria
November 29, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RCXINFLMU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections
-
International Centre for Diarrhoeal Disease Research...Centers for Disease Control and PreventionNot yet recruitingMeasles | Rubella | Cholera | Typhoid
-
MJM BontenJanssen Research & Development, LLC; Innovative Medicines InitiativeCompletedE.Coli InfectionsUnited States, United Kingdom, Canada, France, Germany, Italy, Japan, Spain
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, MeningococcalGermany, France
-
GlaxoSmithKlineCompletedInfections, MeningococcalGermany
-
GlaxoSmithKlineCompletedInfections, MeningococcalKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, MeningococcalUnited States
-
University of ZurichUnknownEscherichia Coli InfectionsSwitzerland
-
GlaxoSmithKlineCompletedInfections, MeningococcalUnited States
-
GlaxoSmithKlineCompletedInfections, MeningococcalLebanon
Clinical Trials on Cystectomy
-
Shandong Provincial HospitalShandong UniversityCompleted
-
Memorial Sloan Kettering Cancer CenterCompleted
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage II Bladder Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma | Stage 0is Bladder Urothelial Carcinoma | Stage I Bladder Urothelial CarcinomaUnited States
-
Cairo UniversityCompletedBladder Cancer | LaparoscopyEgypt
-
University of FloridaNot yet recruitingUrothelial Carcinoma Bladder
-
University of MichiganCompletedBladder Cancer | Transitional Cell Carcinoma of the BladderUnited States
-
University of MiamiNational Cancer Institute (NCI)CompletedBladder Cancer Requiring CystectomyUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNot yet recruitingBladder Cancer
-
University College, LondonActive, not recruitingBladder CancerUnited Kingdom
-
Assiut UniversityRecruitingUrinary Bladder CancerEgypt